Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 15/20 | 0.42 |
| ▸ | GUCY1B1 | Q02153 | 15/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CFD | P00746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20140172 | 0.99 | GUCY1A1 (0.41) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| Acetic Acid SCHEMBL15065459 | 0.93 | GUCY1A1 (0.46) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL14777070 | 0.90 | CFD (0.38) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL18999259 | 0.88 | CNR1 (0.38) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL13734557 | 0.87 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL20161332 | 0.85 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL14776861 | 0.81 | GUCY1A1 (0.34) | GUCY1A1GUCY1B1 | |
| SCHEMBL10071130 | 0.81 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1 | |
| SCHEMBL13733845 | 0.80 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL10070141 | 0.78 | GUCY1A1 (0.40) | GUCY1A1GUCY1B1FEN1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458066-B1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-108738320-B | cGMP modulators for the treatment of cardiovascular diseases | 默沙东公司 | 2021-11-19 | — | — | CN | disclosed |
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3394067-B1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | US | disclosed |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3458066-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | Merck Sharp & Dohme Corp. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20180305366-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2018-10-25 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-8765769-B2 | Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765769-B2 | Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
| WO-2012004259-A1 | RING-FUSED 4 -AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | GUCY1B1, GUCY1A2, GUCY1B2 | GUCY1A1 4/4885GUCY1B1 1/4885CNR1 2211/4885 |
| US-20180305366-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | GUCY1A1 1/4885GUCY1B1 4/4885CNR1 445/4885 |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE2A | GUCY1A1 2/4885GUCY1B1 8/4885CNR1 1182/4885 |
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | PDE2A, PDE3A, PDE5A | GUCY1A1 4/4885GUCY1B1 6/4885CNR1 716/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | GUCY1A1 1/4885GUCY1B1 4/4885CNR1 445/4885 |
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | PDE2A, PDE3A, PDE5A | GUCY1A1 4/4885GUCY1B1 6/4885CNR1 698/4885 |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | GUCY1A1 1/4885GUCY1B1 4/4885CNR1 445/4885 |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | TYMP, DPYD, TYMS | GUCY1A1 3578/4885GUCY1B1 2644/4885CNR1 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.